|
|
|
|
|||||
|
|
|
New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.
HCA Healthcare, Inc. HCA reported fourth-quarter 2025 adjusted earnings per share (EPS) of $8.01, which outpaced the Zacks Consensus Estimate by 8.8%. The bottom line advanced 28.8% year over year.
Revenues rose 6.7% year over year to $19.5 billion. However, the top line lagged the consensus mark by 0.6%.
The quarterly results benefited on the back of strong same-facility admissions and equivalent admissions. Modest gains in emergency room visits and a rise in revenue per equivalent admission also supported performance. However, the upside was partly offset by elevated operating expenses.
HCA Healthcare, Inc. price-consensus-eps-surprise-chart | HCA Healthcare, Inc. Quote
Same-facility equivalent admissions grew 2.5% year over year in the fourth quarter, matching our growth estimate. Meanwhile, same-facility admissions advanced 2.4%, matching our growth estimate.
Same-facility revenue per equivalent admission rose 2.9% year over year but came lower than our growth estimate of 4.2%.
Same-facility inpatient surgeries remained unchanged year over year, while same-facility outpatient surgeries dipped 0.5%. Additionally, same-facility emergency room visits inched up 0.5% year over year in the quarter under review.
Salaries and benefits, supplies and other operating expenses increased 5.8% year over year to $15.4 billion. However, the metric came lower than our estimate of $15.6 billion.
Adjusted EBITDA of $4.1 billion advanced 10.8% year over year, which surpassed our estimate of $3.9 billion.
HCA Healthcare operated 190 hospitals and roughly 2,500 ambulatory sites of care across 19 states and the United Kingdom as of Dec. 31, 2025.
HCA Healthcare exited the fourth quarter with cash and cash equivalents of $1 billion, which dropped 46.2% from the 2024-end level. It had a leftover capacity of approximately $5.8 billion under its credit facilities at the fourth-quarter end.
Total assets of $60.7 billion increased 2% from the figure at 2024-end.
Long-term debt, excluding debt issuance costs and discounts, was $41.6 billion, up 8.5% from the figure as of Dec. 31, 2024. Short-term borrowings and long-term debt due within one year totaled $4.9 billion.
Capital expenditures were $1.5 billion minus acquisitions during the quarter under review.
HCA Healthcare generated $12.6 billion in cash from operations in 2025, which improved 20.2% from the prior-year comparable period.
HCA bought back shares worth $2.6 billion in the fourth quarter. It had a leftover capacity of $750 million under its buyback authorization as of Dec. 31, 2025. Management sanctioned an additional share buyback program of $10 billion.
The board of directors approved an 8.3% hike in the quarterly cash dividend. The increased dividend, amounting to 78 cents per share, will be paid on March 31, 2026, to its shareholders of record as of March 17.
HCA Healthcare’s revenues grew 7.1% year over year to $75.6 billion. Full-year EPS of $28.21 climbed 28.5% year over year. Adjusted EBITDA improved 12.1% year over year to $15.6 billion.
Annual revenues are anticipated to be between $76.5 billion and $80 billion, the midpoint of which indicates a 3.5% rise from the 2025 reported figure.
Management forecasts adjusted EBITDA to be in the range of $15.55-$16.45 billion, the midpoint of which suggests 2.8% growth from the 2025 figure.
Net income attributable to HCA Healthcare is presently expected to be between $6.495 billion and $7.035 billion.
EPS is forecasted to be in the $29.10-$31.50 band, the midpoint of which implies a 7% rise from the 2025 figure.
Capital expenditures, excluding acquisitions, are expected between $5 billion and $5.5 billion.
HCA Healthcare currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Here are three other companies from the Medical space that are likely to report their respective quarterly earnings soon.
Soleno Therapeutics, Inc. SLNO has an Earnings ESP of +15.02% and a Zacks Rank of 1 at present.
The Zacks Consensus Estimate for SLNO’s fourth-quarter 2025 earnings is 59 cents per share. A loss of $1.27 per share was incurred in the prior-year quarter. The consensus mark for fourth-quarter earnings has been revised 9.3% upward over the past seven days.
Amneal Pharmaceuticals, Inc. AMRX has an Earnings ESP of +11.77% and a Zacks Rank of 2 at present. The Zacks Consensus Estimate for AMRX’s fourth-quarter 2025 earnings is 17 cents per share, which indicates a 41.7% surge from the prior-year quarter
Amneal Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed the mark once, the average surprise being 22.42%.
DexCom, Inc. DXCM has an Earnings ESP of +4.91% and a Zacks Rank of 3 at present.
The Zacks Consensus Estimate for DXCM’s fourth-quarter 2025 earnings is 65 cents per share, which indicates a 44.4% surge from the prior-year quarter. DexCom’s earnings beat estimates in two of the trailing four quarters and missed the mark twice, the average surprise being 0.17%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 5 min | |
| 1 hour | |
| 3 hours | |
| 3 hours | |
| 3 hours |
HCA Healthcare Tries To Break Out As Earnings, Outlook, Buyback Overcome This Blemish
HCA +6.94%
Investor's Business Daily
|
| 4 hours | |
| 4 hours | |
| 4 hours | |
| 6 hours | |
| 6 hours | |
| 7 hours | |
| 7 hours | |
| 8 hours | |
| 8 hours |
Could 2026 Be Dexcom's 'Get Right' Year? New CEO Jake Leach Says Yes.
DXCM
Investor's Business Daily
|
| 8 hours |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite